- 1. MoAb 3H1 anti-idiotype vaccine
- [A recombinant monoclonal antibody in which the heavy and light chain variable domains mimic a specific epitope of the tumor-associated protein carcinoembryonic antigen (CEA). This agent is used as a cancer vaccine against tumors that express CEA. (NCI04) ( NCI )] (UMLS (NCI) C0393051) =Amino Acid, Peptide, or Protein; Pharmacologic Substance; Immunologic Factor
| - 10. MOAB Lym-1, yttrium Y 90
- [A radioimmunoconjugate of a murine monoclonal antibody, MoAb Lym-1, labeled with yttrium 90 (Y-90). MoAb Lym-1 recognizes an epitope of the histocompatibility antigen HLA-DR, which is over-expressed on most B-cell lymphomas. Y-90 MoAb Lym-1 delivers Y-90 radionuclide directly to tumor cells that express HLA-DR antigen, thereby may be used in radioimmunotherapy of cancers. ( NCI )] (UMLS (NCI) C0796675) monoclonal antibody Lym-1, yttrium Y 90;
Y 90 MoAb Lym-1;
Y 90 Monoclonal Antibody Lym-1;
yttrium Y 90 MOAB Lym-1;
Yttrium Y 90 Monoclonal Antibody Lym-1 =Pharmacologic Substance; Immunologic Factor ;
|
- 2. MOAB BrE-3, Yttrium Y 90
- [A radioimmunotherapeutic agent consisting of a monoclonal antibody (BrE-3) directed against the tumor-associated antigen epithelial glycoprotein mucin chelated to the radioisotope yttrium-90. Yttrium Y 90 monoclonal antibody BrE-3 binds to tumor cells expressing epithelial glycoprotein mucin, selectively delivering a cytotoxic dose of beta radiation. (NCI04) ( NCI )] (UMLS (NCI) C0935731) Yttrium Y 90 Monoclonal Antibody BrE-3 =Amino Acid, Peptide, or Protein; Pharmacologic Substance; Immunologic Factor
| - 11. MOAB m170, yttrium Y 90
- [A radioimmunoconjugate of m170 monoclonal antibody (MoAb) conjugated with isotope yttrium 90. MoAb m170 is a murine MoAb that recognizes MUC-1 antigen present on the surface of many adenocarcinomas. This radioimmunoconjugate emits beta particles that causes cytotoxicity in tumor cells and has both imaging and therapeutic uses. ( NCI )] (UMLS (NCI) C0796669) monoclonal antibody m170, yttrium Y 90;
Y 90 MoAb m170;
Y 90 Monoclonal Antibody m170;
yttrium Y 90 MOAB m170;
Yttrium Y 90 Monoclonal Antibody m170 =Amino Acid, Peptide, or Protein; Pharmacologic Substance; Immunologic Factor |
- 3. MOAB CC49-deltaCH2
- [A humanized CH2 domain-deleted second-generation monoclonal antibody based on the antibody B72.3 that is directed against tumor-associated glycoprotein 72 (TAG72). TAG72 is expressed by gastric, breast, pancreatic, colorectal, and ovarian carcinoma cells. (NCI04) ( NCI )] (UMLS (NCI) C1134500) MOAB HCC49DCH2;
MoAb HuCC49DeltaCH2;
Monoclonal Antibody CC49-delta CH2;
Monoclonal Antibody HCC49DCH2 =Amino Acid, Peptide, or Protein; Pharmacologic Substance; Immunologic Factor | - 12. MOAB M195, yttrium Y 90
- [A radioimmunoconjugate of humanized M195 monoclonal antibody (MoAb) conjugated with isotope yttrium 90. MoAb M195 is reactive with the cell surface antigen CD33, a glycoprotein found on myeloid leukemia blasts and early hematopoietic progenitor cells but not on normal stem cells. This radioimmunoconjugate emits beta particles that causes cytotoxicity in tumor cells and has both imaging and therapeutic uses. ( NCI )] (UMLS (NCI) C0879572) monoclonal antibody M195, yttrium Y 90;
Y 90 MoAb M195;
Y 90 Monoclonal Antibody M195;
Yttrium Y 90 Monoclonal Antibody M195 =Amino Acid, Peptide, or Protein; Pharmacologic Substance; Immunologic Factor |
- 4. MoAb CD20
- (UMLS (NCI) C0796614) monoclonal antibody, CD20 =Amino Acid, Peptide, or Protein; Pharmacologic Substance; Immunologic Factor
| - 13. MOAB MN-14, yttrium Y 90
- [A radioimmunotherapeutic monoclonal antibody (MN-14) directed against tumor-associated carcinoembryonic antigen (CEA) and chelated to the radioisotope yttrium-90 (Y 90). Yttrium 90 monoclonal antibody MN-14 binds to tumor cell expressing CEA, delivering a cytotoxic dose of beta radiation. (NCI04) ( NCI )] (UMLS (NCI) C0879253) monoclonal antibody MN-14, yttrium Y 90;
Y 90 MoAb MN-14;
Y 90 Monoclonal Antibody MN-14;
Yttrium 90 Monoclonal Antibody MN-14;
yttrium Y 90 MOAB MN-14;
Yttrium Y 90 Monoclonal Antibody MN-14 =Amino Acid, Peptide, or Protein; Pharmacologic Substance; Immunologic Factor |
- 5. MoAb D6.12
- [A murine IgG2a monoclonal antibody directed against a 48 kDa antigen expressed on the cell surface of normal and malignant gastrointestinal epithelium. MoAb D6.12 has been shown to induce antibody-dependent cell-mediated cytotoxicity (ADCC). This MoAb, either alone or in combination with other immunotherapeutic agents, may have possible diagnostic or therapeutic applications in gastrointestinal cancers. ( NCI )] (UMLS (NCI) C1134661) MoAb D612;
Monoclonal Antibody D6.12;
=Amino Acid, Peptide, or Protein; Pharmacologic Substance; Immunologic Factor | - 14. MoAb muJ591
- [A type of monoclonal antibody used in cancer detection or therapy. Monoclonal antibodies are laboratory-produced substances that can locate and bind to cancer cells. ( NCI )] (UMLS (NCI) C0678086) =Amino Acid, Peptide, or Protein; Pharmacologic Substance; Immunologic Factor
|
- 6. MOAB HER2/TAX
- (UMLS (NCI) C0338364) =Therapeutic or Preventive Procedure
| - 15. MoAb MX35 F(ab')2
- [The F(ab)2 fragment of monoclonal antibody (MoAb) MX35 that recognizes a 95 kD glycoprotein with homogeneous distribution on 80% of ovarian tumor specimens. When radiolabeled, this MoAb has potential use in the radioimaging or may induce a cytotoxic T-cell response against tumor cell that express this glycoprotein. Containing only the antigen-binding fragment of the Ig molecule, MoAb MX35 F(ab')2 offers the advantages of smaller size and lower cross-reactivity compared to complete antibodies. ( NCI )] (UMLS (NCI) C0393012) =Amino Acid, Peptide, or Protein; Pharmacologic Substance; Immunologic Factor
|
- 7. MOAB HMFG1, yttrium Y 90
- [A radioimmunoconjugate of humanized monoclonal antibody (MoAb) HMFG1 labelled with Yttrium 90 (Y-90). MoAb MFG1 was raised against Human Milk Fat Globules and reacts with an epitope (PDTR) in the protein core of MUC1 mucins, which are up-regulated in human breast and other carcinomas.Y-90 MoAb HMFG1 delivers beta particle emitting Y-90 radionuclide directly to tumor cells that express MUC1, thereby may be used in radioimmunotherapy of cancers. ( NCI )] (UMLS (NCI) C0879349) monoclonal antibody HMFG1, yttrium Y 90;
Y 90 MoAb HMFG1;
Y 90 Monoclonal Antibody HMFG1;
yttrium Y 90 MOAB HMFG1;
Yttrium Y 90 Monoclonal Antibody HMFG1 =Amino Acid, Peptide, or Protein; Pharmacologic Substance; Immunologic Factor | - 16. MoAb R24
- [An IgG murine monoclonal antibody directed against the ganglioside GD3 glycolipid, located in the cell membranes of some tumor cells. Monoclonal antibody R24 binds to GD3-positive cells, thereby initiating antibody-dependent cytotoxicity against GD3-positive cells. (NCI04) ( NCI )] (UMLS (NCI) C0279226) =Amino Acid, Peptide, or Protein; Pharmacologic Substance; Immunologic Factor
|
- 8. MoAb Hu1D10
- (UMLS (NCI) C0879351) MoAb: Hu1D10;
Monoclonal antibody 1D10;
Monoclonal Antibody Hu1D10 =Amino Acid, Peptide, or Protein; Pharmacologic Substance; Immunologic Factor | - 17. Moapa Band of Paiute Indians of the Moapa River In
- (UMLS (HL7) C1554380) =Population Group =NativeEntityContiguous;
|
- 9. MOAB LL2, yttrium Y 90
- [A radioimmunotherapeutic humanized murine monoclonal antibody (LL2) directed against the CD22 pan-B-cell antigen and chelated to the radioisotope yttrium-90 (Y 90). Yttrium 90 humanized epratuzumab binds to tumor cells expressing CD222, delivering a cytotoxic dose of beta radiation. (NCI04) ( NCI )] (UMLS (NCI) C0879352) Monoclonal antibody LL2, yttrium Y 90;
Y 90 Humanized Monoclonal Antibody LL2;
Y 90 MoAb LL2;
Y 90 monoclonal antibody LL2;
Y90 Humanized Epratuzumab;
Yttrium 90 Humanized Epratuzumab;
Yttrium Y 90 Humanized Epratuzumab;
Yttrium Y 90 Humanized Monoclonal Antibody LL2;
yttrium Y 90 MOAB LL2 =Amino Acid, Peptide, or Protein; Pharmacologic Substance; Immunologic Factor | |
home
